Skip to main content

Table 3 Susceptibility antimicrobial against A. baumannii complex

From: Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador

A.baumannii complex blaOXA23 n = 8

A.baumannii complex blaOXA24/40 n = 16

A. baumannii complex n = 24

 

Susceptible

  

Susceptible

  

Susceptible

Antimicrobials

No

%

MIC50 µg/ml

MIC90 µg/ml

No

%

MIC50 µg/ml

MIC90 µg/ml

No

%

AK

0

0.00

 ≥ 64

 ≥ 64

0

0.00

 ≥ 64

 ≥ 64

0

0

GN

0

0.00

 ≥ 64

 ≥ 64

0

0.00

 ≥ 64

 ≥ 64

0

0

CIP

0

0.00

 ≥ 4

 ≥ 4

0

0.00

 ≥ 4

 ≥ 4

0

0

SXT

0

0.00

4/76

4/76

0

0.00

4/76

4/76

0

0

COL

6a

100.00

1

1

13b

92.86

1

1

19 ± 

95

CAZ

2

25.00

 ≥ 64

 ≥ 64

2

12.50

 ≥ 64

 ≥ 64

4

18.18

FEP

0

0.00

 ≥ 32

 ≥ 32

0

0.00

16

 ≥ 32

0

0

IMP

0

0.00

 ≥ 16

 ≥ 16

0

0.00

 ≥ 16

 ≥ 16

0

0

MERO

0

0.00

 ≥ 16

 ≥ 16

0

0.00

 ≥ 16

 ≥ 16

0

0

PTZ

0

0.00

 ≥ 128/4

 ≥ 128/4

0

0.00

 ≥ 128/4

 ≥ 128/4

0

0

SAM

0

0.00

 ≥ 32/16

 ≥ 32/16

2

12.50

 ≥ 32/16

 ≥ 32/16

2

8.33

  1. AK Amikacin, GN Gentamicin, CIP Ciprofloxacin, SXT Trimethoprim/sulfamethoxazole, COL Colistin, CAZ Ceftazidime, FEP Cefepime, IMP Imipenem, MER Meropenem, PTZ Piperacillin/tazobactam, SAM Ampicillin/sulbactam
  2. a6 isolates tested
  3. b14 isolates tested ± 20 isolates tested